Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Engineered OX40L CAR-Tregs
- Development stage
- Preclinical
- Lead developer
- Regatta Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Engineered OX40L CAR-Tregs (v2.1) is a preclinical-stage cell therapy candidate developed by Regatta Medical (Regatta Bio) for the treatment of transplant rejection and autoimmune diseases. The therapy utilizes regulatory T cells (Tregs) that have been genetically modified to express a chimeric antigen receptor (CAR) specific for OX40 ligand (OX40L, TNFSF4). This approach is designed to enhance the specificity and potency of the Tregs by targeting activated antigen-presenting cells (APCs) that express OX40L, thereby modulating alloreactive immune responses and promoting immune tolerance. A distinguishing feature of the v2.1 candidate is its engineering for IL-2 independence, which aims to improve the persistence and suppressive function of the CAR-Tregs in vivo without the requirement for exogenous IL-2 supplementation.
- Other names
- OX40L CAR-TregsOX-40L CAR-TregsOX 40L CAR-TregsOX40L-CAR-TregsOX-40L-CAR-TregsOX 40L-CAR-Tregs
02
Targets
TNFSF4 (Tumor necrosis factor ligand superfamily member 4)
Beyond the preview
Go deeper on Engineered OX40L CAR-Tregs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Engineered OX40L CAR-Tregs.